Blog
GLP-1 Weight Loss Clinical Trials Compared
Headlines about percent weight loss are everywhere, but numbers mean little without context. This article puts GLP-1 weight loss clinical trials side by side and shows how to read them honestly.
Semaglutide: the STEP program
STEP 1 enrolled adults with overweight or obesity without diabetes and ran 68 weeks. The semaglutide group averaged about 14.9 percent body weight reduction against about 2.4 percent with placebo, alongside lifestyle intervention in both groups.
Most participants in the treatment arm lost at least 5 percent of body weight, and a large share lost 10 or 15 percent.
Tirzepatide: SURMOUNT-1
SURMOUNT-1 ran 72 weeks and tested 5, 10 and 15 mg. Average weight reductions were about 15.0, 19.5 and 20.9 percent versus about 3.1 percent with placebo.
A notable portion of participants on the highest dose lost 25 percent or more of body weight.
Retatrutide: phase 2
The phase 2 obesity trial lasted 48 weeks and tested several doses. At the highest dose, average weight loss reached about 24.2 percent versus about 2.1 percent with placebo, and the curves had not fully flattened at the end of the study.
Larger phase 3 programs were underway, so check the latest publications.
Why you cannot compare them directly
The trials differed in duration, dose escalation schedules, populations, baseline weight and lifestyle support. A 48 week trial cannot be compared fairly with a 72 week trial.
Only head-to-head studies answer which compound is better, and even those depend on the population studied.
What the trials share
All three showed rapid early loss, a slowing curve and mostly gastrointestinal side effects that were most common during dose escalation. All three also showed improvements in several metabolic markers.
These trial results help explain why GLP-class compounds dominate metabolic research. They are clinical findings about regulated drugs under medical supervision, and they are not instructions for anyone.
Reading trial data like a researcher
Look at the endpoint (percent change or absolute kilograms), the analysis method (treatment-regimen or on-treatment), dropout rates and the control group. Treatment-regimen estimates are typically more conservative.
Our overview of the three GLP types gives the mechanism behind the numbers.
How to read the literature on GLP-1 weight loss clinical trials
Start with the type of evidence. A cell assay shows a mechanism, an animal study shows a system-level effect, and a controlled clinical trial shows what happens in a defined human population. Next, check the controls, the duration and whether the analysis was pre-specified. Finally, look at who funded the study and whether independent groups have replicated the finding.
Be careful with summaries that blend trials, mechanisms and anecdotes. When reading about GLP-1 weight loss clinical trials, trace each statement back to the original paper and note the dose, duration and population.
A practical research checklist for GLP-1 weight loss clinical trials
- Define one narrow question before choosing a model.
- Match the measurement to the biology, such as cAMP assays for receptors or DXA for body composition.
- Record peptide source, lot number, purity and storage for every run.
- Reconstitute carefully and avoid repeated freeze and thaw cycles.
- Replicate key results before building on them.
Key takeaways
- Semaglutide about 15 percent, tirzepatide up to about 21 percent, retatrutide up to about 24 percent in separate trials.
- Cross-trial comparisons are unreliable.
- Check duration, population and analysis method.
- Trial results are not use guidance.
Frequently asked questions about GLP-1 weight loss clinical trials
Is this information medical advice?
No. This article summarizes published scientific research for educational purposes. It is not medical advice, and anyone with a health concern should speak with a qualified clinician.
Are the products on this site for human use?
No. Every compound sold by Lucid Aminos is for laboratory research use only and is not intended for human consumption or to diagnose, treat or prevent any condition.
Where can I verify the quality of a batch?
Each lot has its own certificate of analysis on the COA page, and you can browse all compounds in the research compound shop.
Browse the research compounds
Researchers following this topic often work with GLP2-TZ, GLP3-RT, Bacteriostatic Water. Every batch has its own report on the COA page, and you can browse the full shop for all research compounds.
Related reading
Educational content only. All compounds sold by Lucid Aminos are for laboratory research use only and are not for human consumption. This article is not medical advice. If you are concerned about hair loss or scalp problems, speak with a qualified clinician.
Explore Lucid Aminos
- Shop all research compounds
- Read the lab reports (COA)
- Frequently asked questions
- Partner program
- About Lucid Aminos
- Contact us
For laboratory research use only. Not for human or veterinary use, and not intended to diagnose, treat, cure or prevent any condition. This article is educational and is not medical advice.